- Home
- FRMI vs LEGN Comparison
FRMI vs LEGN Comparison
Compare FRMI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRMI | LEGN |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FRMI | LEGN |
|---|---|---|
| Price | $8.11 | $19.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 14 |
| Target Price | $29.50 | ★ $63.46 |
| AVG Volume (30 Days) | ★ 6.9M | 2.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $67.56 |
| Revenue Next Year | $3,427.92 | $43.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.18 | $16.24 |
| 52 Week High | $32.39 | $45.30 |
Technical Indicators
Market Signals| Indicator | FRMI | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.46 | 55.82 |
| Support Level | $7.23 | $16.24 |
| Resistance Level | $10.57 | $21.58 |
| Average True Range (ATR) | 0.89 | 0.91 |
| MACD | -0.20 | 0.20 |
| Stochastic Oscillator | 11.02 | 51.70 |
Price Performance
Historical ComparisonAbout FRMI Fermi Inc.
Fermi Inc is an energy and hyperscaler development company purpose-built for the AI era. Its Project Matador, a multi-gigawatt energy and data center development campus designed to support the accelerating needs of to-be-built AI infrastructure. Through its REIT structure, Fermi offers investors exposure to AI infrastructure growth and long-term, large-scale and reliable energy development in a tax-efficient public vehicle.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.